Owlet Dream Sock: FDA Cleared Infant SpO2 and Heart Rate Monitor for Home Use

The first FDA cleared consumer pulse oximetry monitor designed specifically for infants, offering continuous SpO2 and heart rate tracking from a soft fabric sock worn during sleep.

Presented By Our Partners

Every year in the United States, approximately 3,400 infants die suddenly and unexpectedly during sleep. The causes include sudden infant death syndrome (SIDS), accidental suffocation, and strangulation in the sleeping environment. For decades, parents have searched for technology that could provide an early warning if something went wrong during the night. Hospital neonatal units have long used continuous pulse oximetry to monitor at risk infants, but bringing that capability into the home proved technically and regulatorily challenging.

A 2025 review published in Annals of Biomedical Engineering by Tehrani examined the primary physiological mechanisms behind SIDS, concluding that immature arterial and central respiratory chemoreceptors during a critical developmental period are the primary contributors to prolonged apneic episodes, and that home pulse oximetry monitoring during sleep could detect dangerous oxygen desaturation events and trigger alarms that may save infant lives. The gap between what hospitals monitor and what parents can observe at home has been one of the most anxiety producing blind spots in pediatric care.

The Owlet Dream Sock is the first consumer infant monitor to receive FDA De Novo authorization (a pathway for novel devices without a predicate) for pulse oximetry in infants. After a complex regulatory journey that included an FDA warning letter in 2021 and a voluntary market withdrawal, Owlet returned with formal clearance in 2023, transforming a controversial consumer product into a regulated medical device. The distinction matters: the Owlet Dream Sock is not a general wellness gadget. It is an FDA authorized pulse oximeter designed to measure oxygen saturation and heart rate in infants aged 0 to 5 years.

What Is the Owlet Dream Sock?

The Owlet Dream Sock is a fabric sock embedded with pulse oximetry sensors that wraps around an infant’s foot to continuously measure blood oxygen saturation (SpO2) and heart rate during sleep. The sensor module clips into the sock, communicates wirelessly to a base station (the Owlet Dream Hub), and transmits data to a companion smartphone app where parents can view real time readings and historical trends.

The system notifies parents if the infant’s oxygen level or heart rate falls outside preset thresholds. The base station provides audible and visual alerts, and the app delivers push notifications to the parent’s phone. The sock is designed for overnight use and is available in multiple sizes to accommodate infants from birth through age five (approximately 6 to 55 pounds).

The device uses pulse oximetry, the same photoplethysmography technology found in hospital pulse oximeters, adapted into a soft, wearable form factor suitable for a sleeping infant. Two LEDs (red and infrared) shine through the skin of the foot, and a photodetector measures the ratio of absorbed light to calculate oxygen saturation and pulse rate. The sock connects via Bluetooth to the base station, which connects to the home Wi-Fi network for app communication. Battery life is approximately 16 hours per charge, more than sufficient for overnight monitoring sessions.

The Science Behind Infant Pulse Oximetry Monitoring

Pulse oximetry is one of the most important vital sign measurements in modern medicine. It provides a noninvasive, continuous estimate of arterial oxygen saturation by exploiting the differential light absorption properties of oxygenated and deoxygenated hemoglobin. In hospital settings, pulse oximetry has been standard of care in neonatal intensive care units for decades, credited with reducing undetected hypoxemic events and improving outcomes for premature and critically ill infants.

The physiological rationale for home infant monitoring centers on the detection of hypoxemia, a dangerous drop in blood oxygen that can precede or accompany apneic events, respiratory infections, and other life threatening conditions. According to PubMed, the 2025 review by Tehrani in Annals of Biomedical Engineering confirmed that SIDS is primarily caused by the prematurity of arterial and central respiratory chemoreceptors during a developmental period, and that pulse oximetry monitoring during sleep could detect the resulting oxygen desaturation episodes. The review recommended home pulse oximetry as a potential intervention for high risk infants.

It is important to note, however, that the medical establishment has been cautious about recommending home cardiorespiratory monitors for SIDS prevention. The American Academy of Pediatrics (AAP) has stated that home apnea monitors have not been shown to reduce the incidence of SIDS. The reasoning is multifaceted: false alarms can cause unnecessary anxiety, true alarms do not guarantee successful intervention, and safe sleep practices (supine positioning, firm sleep surface, no soft bedding) remain the evidence based foundation for SIDS risk reduction.

A 2020 multicenter study published in JAMA by Bonafide et al. examined pulse oximetry use in hospitalized children with bronchiolitis who did not require supplemental oxygen, finding that 46% were still continuously monitored, a practice the authors characterized as potential overuse. This finding illustrates a broader tension in oxygen monitoring: the technology detects real events, but the clinical significance and appropriate response to every detected event are not always clear. The same tension applies to home infant monitoring, where a low SpO2 reading may reflect sensor displacement, normal transitional breathing, or a genuine emergency.

Within Healthcare Discovery‘s longevity framework, infant health monitoring occupies a unique position. While the Four Villains (cardiovascular disease, cancer, neurodegenerative disease, metabolic dysfunction) typically frame adult healthspan discussions, the foundational principle of early detection and intervention applies across the lifespan. For parents of newborns, the question is not theoretical: it is whether technology can provide a meaningful safety layer during the most vulnerable period of human life. That is the science. Here is how the Owlet Dream Sock applies it.

What the Owlet Dream Sock Does Well

The Owlet Dream Sock’s primary achievement is regulatory. By obtaining FDA De Novo authorization, Owlet established that its device meets the safety and effectiveness standards required of a medical device for infant pulse oximetry. This is not a marketing claim or a general wellness classification. The FDA reviewed clinical data and determined that the device could be marketed as a pulse oximeter for infants. For parents who previously had to choose between unregulated consumer monitors and clinical grade equipment available only in hospitals, this represents a genuine category advance.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The form factor is thoughtfully designed for the specific challenges of monitoring a sleeping infant. The soft fabric sock minimizes discomfort and stays in place better than clip style sensors, which are difficult to secure on tiny infant feet. The wireless connectivity eliminates cables that could pose entanglement risks. The base station provides whole room audible alerts that can wake sleeping parents, while the app provides remote monitoring capability for parents who are in another part of the house.

The companion app provides sleep trend data over time, allowing parents and pediatricians to review patterns in oxygen saturation and heart rate across nights and weeks. For infants with known risk factors (prematurity, congenital heart conditions, respiratory issues), this longitudinal data can inform clinical conversations and care decisions. The ability to share data with a healthcare provider elevates the Owlet from a consumer anxiety tool to a potential clinical information source.

Pricing, Access, and Practical Realities

The Owlet Dream Sock retails at $299. The companion app requires a subscription of $9.99 per month ($119.88 per year) to access real time monitoring, historical data, and notification features. First year total cost of ownership is approximately $419 when combining the device and 12 months of subscription. Without the subscription, the device functions as a basic monitor with limited functionality.

The Owlet Dream Sock holds FDA De Novo authorization for pulse oximetry in infants. This is a specific and important regulatory classification: De Novo is a pathway for novel medical devices that have no substantially equivalent predicate device. It is neither a 510(k) clearance (which requires a predicate) nor a full premarket approval (PMA). The authorization means the FDA reviewed the device and determined it met regulatory standards for safety and effectiveness as a pulse oximeter. It does not mean the device is authorized to prevent, diagnose, or treat SIDS or any other specific condition.

HSA and FSA eligibility is confirmed for the Owlet Dream Sock. As an FDA authorized medical device, it qualifies for purchase with health savings account and flexible spending account funds, which can offset the cost for families with these benefit structures. The subscription cost may also qualify, though families should verify with their specific plan administrator.

Who the Owlet Dream Sock Is Best For

The Owlet Dream Sock is designed for parents of infants from birth through age five who want continuous overnight monitoring of blood oxygen saturation and heart rate. It is particularly relevant for families with infants who have known risk factors: premature birth, low birth weight, siblings who experienced SIDS, congenital heart or respiratory conditions, or any clinical history that their pediatrician deems worthy of home monitoring. Parents who experience significant anxiety about their infant’s sleep safety and who understand the device’s capabilities and limitations may also find it valuable as one component of a broader safe sleep strategy.

Pediatricians and neonatologists who want their patients to have home SpO2 monitoring between clinical visits now have an FDA authorized option to recommend, which lowers the professional risk of suggesting an unregulated consumer product.

Those who may want to skip the Owlet Dream Sock include families who are primarily seeking SIDS prevention (the device is not authorized for this purpose and the AAP does not recommend home monitors for SIDS reduction), parents who are prone to severe health anxiety and may find frequent alerts more distressing than reassuring, and budget constrained families for whom the $419 first year cost is prohibitive. Parents should also be aware that no home monitor replaces the evidence based safe sleep practices recommended by the AAP.

How the Owlet Dream Sock Compares

The Owlet Dream Sock occupies a unique regulatory position: it is currently the only FDA De Novo authorized consumer pulse oximeter specifically designed for infants. This creates a comparison landscape where alternatives are either unregulated consumer products or clinical grade hospital equipment.

The Nanit Pro Camera ($299, plus $100/year subscription) takes an entirely different approach, using computer vision to monitor infant breathing motion through a wall mounted camera without any wearable component. Nanit does not measure SpO2 or heart rate; it detects breathing motion. It is classified as a general wellness device, not an FDA authorized medical device. For parents who want contactless monitoring and sleep analytics, Nanit is a strong option. For parents who want actual physiological measurement (oxygen saturation and pulse rate), the Owlet provides data that Nanit cannot.

The Miku Pro Smart Baby Monitor ($399) similarly uses radar based contactless breathing detection without a wearable. Like Nanit, it measures breathing motion, not blood oxygen. Hospital grade infant pulse oximeters (such as the Masimo Rad 97) provide clinical accuracy but cost $1,000 or more, require a prescription, and are designed for clinical settings rather than home use. The Owlet Dream Sock sits in the gap between these clinical devices and the camera based consumer monitors, offering physiological measurement in a consumer friendly form factor with regulatory backing.

Limitations and Open Questions

The most important limitation of the Owlet Dream Sock is what it cannot do: it cannot prevent SIDS or any other cause of infant death. The American Academy of Pediatrics does not recommend home cardiorespiratory monitors for SIDS prevention, and the Owlet’s FDA authorization is specifically for pulse oximetry measurement, not for any diagnostic or preventive claim. Parents who purchase the device expecting it to eliminate the risk of sudden infant death will be disappointed and potentially misled.

False alarms are a well documented challenge with consumer pulse oximetry. Sensor displacement, motion artifact, poor peripheral perfusion (cold feet), and skin pigmentation can all produce inaccurate readings or spurious alerts. In a sleeping infant, sensor displacement is particularly common as the baby moves during sleep. Each false alarm disrupts parental sleep, increases anxiety, and can lead to “alarm fatigue” where parents begin ignoring notifications, potentially including genuine alerts.

The $9.99 monthly subscription creates a recurring cost that compounds significantly over the one to five year usage window. A family monitoring from birth through age two would pay approximately $539 in total ($299 device plus $240 in subscription fees). The subscription model also means that if the service is discontinued or the company changes its pricing, families lose access to features they depend on. Data privacy is an additional consideration: continuous physiological data from an infant is among the most sensitive information a family can generate, and parents should review the company’s data handling policies carefully.

What This Means for Your Health

The Owlet Dream Sock represents something genuinely new in consumer health technology: an FDA authorized medical device designed to bring hospital grade vital sign monitoring into the home for the most vulnerable patient population. The regulatory journey that Owlet navigated, from FDA warning letter to voluntary withdrawal to formal De Novo authorization, reflects the tension between parental demand for safety technology and the regulatory system’s insistence on demonstrated safety and effectiveness before marketing claims can be made.

Within HealthcareDiscovery.ai’s framework, the Owlet Dream Sock connects to a foundational principle that applies across the entire lifespan: early detection of physiological deviation creates the opportunity for intervention. For adults, this principle drives the wearable monitoring ecosystem for heart rate variability, blood glucose, and blood oxygen. For infants, the same principle takes on a more urgent character because the window for intervention during a hypoxemic event is measured in minutes.

The device works best as one layer in a comprehensive approach to infant sleep safety. The evidence based foundation remains the ABCs of safe sleep: Alone (no bed sharing), on the Back (supine position), in a Crib (firm, flat surface with no soft bedding). No monitor, however sophisticated, substitutes for these practices. But for families who have implemented safe sleep guidelines and want an additional layer of physiological monitoring, the Owlet Dream Sock now provides that layer with the regulatory backing that was absent from the consumer market until recently. For parents navigating the most anxious months of their child’s life, the ability to see a real time oxygen saturation reading may not eliminate worry, but it provides a data point where previously there was only darkness.

Frequently Asked Questions

Is the Owlet Dream Sock FDA approved?
The Owlet Dream Sock holds FDA De Novo authorization, which is a regulatory pathway for novel medical devices without a substantially equivalent predicate. This is distinct from FDA 510(k) clearance or full premarket approval (PMA). The De Novo authorization means the FDA reviewed the device and determined it meets regulatory standards for safety and effectiveness as a pulse oximeter for infants. It is authorized to measure SpO2 and heart rate; it is not authorized to prevent, diagnose, or treat SIDS or any specific condition.

Does the Owlet Dream Sock prevent SIDS?
No. The Owlet Dream Sock is not authorized, designed, or marketed to prevent SIDS. The American Academy of Pediatrics does not recommend home cardiorespiratory monitors for SIDS prevention. The device measures oxygen saturation and heart rate and notifies parents if readings fall outside preset thresholds, but detection is not the same as prevention. Safe sleep practices (supine position, firm surface, no soft bedding, room sharing without bed sharing) remain the evidence based foundation for reducing SIDS risk.

How much does the Owlet Dream Sock cost per year?
The device retails at $299. The companion app subscription is $9.99 per month ($119.88 per year). First year total cost is approximately $419. The device is HSA and FSA eligible as an FDA authorized medical device. Without the subscription, the device has limited functionality, so the ongoing cost should be factored into the purchasing decision for the full monitoring period.

How accurate is the Owlet Dream Sock compared to hospital pulse oximeters?
The Owlet Dream Sock uses the same photoplethysmography technology as hospital pulse oximeters, adapted into a wearable sock form factor. As an FDA authorized device, it met regulatory accuracy standards during the De Novo review process. However, consumer wearable pulse oximeters generally have wider accuracy margins than clinical grade devices, and readings can be affected by motion, sensor fit, cold extremities, and skin pigmentation. Parents should treat the device as a screening tool, not a clinical diagnostic instrument.

What ages is the Owlet Dream Sock designed for?
The Owlet Dream Sock is designed for infants and children from birth through approximately age five, accommodating weights from about 6 to 55 pounds. Multiple sock sizes are available to ensure proper sensor contact as the child grows. Most families use the device most intensively during the first 12 to 24 months, when SIDS risk is highest and parental anxiety about sleep safety is greatest.

How does the Owlet compare to camera based baby monitors like Nanit?
The Owlet Dream Sock and Nanit Pro Camera measure fundamentally different things. Owlet measures blood oxygen saturation (SpO2) and heart rate through pulse oximetry, providing physiological data. Nanit uses computer vision to detect breathing motion without any wearable, providing behavioral data. Owlet is FDA De Novo authorized; Nanit is a general wellness device. Owlet costs $299 plus $9.99/month; Nanit costs $299 plus approximately $100/year. The choice depends on whether parents prioritize physiological measurement (Owlet) or contactless convenience (Nanit).

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.